Pair Name	Tiliroside, Sorafenib
Partner Name	Sorafenib
Disease Info	[ICD-11: 2C12]	Hepatocellular carcinoma		Investigative
Biological Phenomena	Induction-->Ferroptosis
Gene Regulation	Down-regulation	Expression	FTH1	hsa2495
	Down-regulation	Expression	G6PD	hsa2539
	Down-regulation	Expression	GPX4	hsa2879
	Up-regulation	Expression	KEAP1	hsa9817
	Down-regulation	Expression	NFE2L2	hsa4780
	Up-regulation	Expression	SQSTM1	hsa8878
	Down-regulation	Phosphorylation	TBK1	hsa29110
In Vitro Model	Hep-G2	Hepatoblastoma	Homo sapiens (Human)	CVCL_0027
In Vivo Model	A total of 2.5×10⁶ HepG2-luciferase cells/100 µl were injected into the left axilla of mice.
Result	Our findings imply that tiliroside is a potent TBK1 inhibitor and a candidate natural anti-cancer product that could function as a sensitizer of sorafenib in HCC treatment by targeting TBK1 to induce ferroptosis.

Pair Name	Tiliroside, Anti-MUC1 antibody
Partner Name	Anti-MUC1 antibody
Disease Info	[ICD-11: 2B72]	Gastric cancer		Investigative
Gene Regulation	Down-regulation	Expression	NFKB1	hsa4790
In Vitro Model	AGS	Gastric adenocarcinoma	Homo sapiens (Human)	CVCL_0139
Result	The combined action of anti-MUC1 and tiliroside was more effective in comparison with monotherapy in the case of C1GalT1, ST3GalT1, FUT4, Gal-3, NF-κB, Akt mRNAs, and Tn antigen, as well as sialyl T antigen expression. The results of our study indicate that applied combined therapy may be a promising anti-gastric cancer strategy.